Cytosorbents Corp (CTSO) Stock Price & Analysis
Cytosorbents Corp (CTSO) rose 2.00% to USD 0.42 as of June 10, 2026 at 05:02 UTC, according to Nexqual real-time market data.
CTSO last closed at USD 0.41; the session ranged USD 0.42–0.47 on volume of 94,469 shares. Market capitalization is $26.53M, with a 52-week range of USD 0.41–1.39 (NCM). Source: Nexqual, June 10, 2026 at 05:02 UTC.
Key Statistics (as of June 10, 2026 at 05:02 UTC)
| Price | USD 0.42 |
|---|---|
| Change | ▲ 2.00% (up) |
| Previous Close | USD 0.41 |
| Open | USD 0.42 |
| Day Range | USD 0.42 – 0.47 |
| 52-Week Range | USD 0.41 – 1.39 |
| Volume | 94,469 shares |
| Market Cap | $26.53M |
| Exchange | NCM |
Technical Analysis (CTSO)
Nexqual's technical model rates CTSO "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.07 (oversold) |
| vs SMA50 | Below (USD 0.56) |
| MACD | -0.04 (negative) |
Analyst Ratings (CTSO)
Wall Street analysts rate CTSO "None" based on 2 analysts, with a mean price target of USD 2.88 (range USD 0.75–5), per Nexqual as of June 10, 2026 at 05:02 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 2.88 |
| High Target | USD 5 |
| Low Target | USD 0.75 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (CTSO)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $9.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.06 ▼ miss |
| 2025-12-31 | USD -0.09 vs est -0.05 ▼ miss |
| 2025-09-30 | USD -0.05 vs est -0.05 ▼ miss |
| 2025-06-30 | USD 0.03 vs est -0.06 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
Financials & Fundamentals (CTSO)
| Total Revenue | $37.20M |
|---|---|
| Revenue Growth (YoY) | +1.60% |
| Gross Margin | +71.00% |
| Operating Margin | -34.34% |
| Profit Margin | -31.85% |
| ROE | -141.58% |
| Debt / Equity | 1,334.37 |
| Current Ratio | 1.09 |
| Total Cash | $4.81M |
| Total Debt | $29.28M |
| Free Cash Flow | $-4.68M |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
Financial Health Score (CTSO)
Nexqual rates Cytosorbents Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:02 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Critical — $5M cash vs $29M debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -142%, ROA -18.3% |
Ownership (CTSO)
| Insider Ownership | +14.85% |
|---|---|
| Institutional Ownership | +26.41% |
| Shares Outstanding | 62.79M |
| Float | 55.09M |
| Short % of Float | +3.40% |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
Leadership (CTSO)
Cytosorbents Corp is led by Phillip P. Chan (age 55), CEO & Director, per Nexqual as of June 10, 2026 at 05:02 UTC.
| CEO & Director | Phillip P. Chan (age 55) |
|---|---|
| President & COO | Vincent J. Capponi M.S. (age 67) |
| Chief Financial Officer | Peter J. Mariani (age 61) |
| Executive Vice President of Sales & Marketing | Christian Steiner |
| Senior Vice President of Business Development | Christopher Cramer M.B.A., M.S. |
Major Backers & Investors (CTSO)
Notable institutional backers of Cytosorbents Corp include Avenir Corp, Neuberger Berman Group, LLC, Skylands Capital, LLC, according to Nexqual as of June 10, 2026 at 05:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avenir Corp | 8.31% |
| Neuberger Berman Group, LLC | 3.71% |
| Skylands Capital, LLC | 2.72% |
| CM Management, LLC | 2.35% |
| Fidelity | 0.95% |
| Sargent Investment Group, LLC | 0.88% |
| Pathstone Holdings, LLC | 0.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.49% |
| BlackRock | 1.48% |
| Geode Capital | 1.13% |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
From Cytosorbents Corp's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally.
- Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
- In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APYX | Apyx Medical Corporation | USD 4.86 | ▲ 8.72% |
| AXGN | AxoGen, Inc. | USD 42.87 | ▲ 0.16% |
| CSBR | Champions Oncology, Inc. | USD 5.79 | ▲ 2.48% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| CUE | Cue Biopharma, Inc. | USD 30.44 | ▲ 3.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:02 UTC. This page is informational and not investment advice.